MilliporeSigma (life sciences operating arm of Merck) announced the opening of its first BioReliance® End-to-End Biodevelopment Center in the Asia Pacific (APAC) region.
The center will provide a full range of process development capabilities and services, including cell line development, upstream and downstream process development and non-GMP clinical production.
The centre will be operated under the BioReliance brand.
The Biodevelopment Center is designed to target customers in the APAC region through an integrated suite of services for biopharmaceutical helping to accelerate clinical drug development from molecule to commercial production.
“Our new BioReliance® End-to-End Biodevelopment Center will host small-scale drug manufacturers working on early-phase clinical trials,” said Udit Batra, CEO, MilliporeSigma.
Udit also added that MilliporeSigma has 30 years of process development experience and a track record of delivering robust clinical production process and clinical material within nine to 12 months.
The opening of this center will provide biopharma and emerging biotech companies to access to the latest technologies and experienced scientists. It also helps to accelerate drug development by providing more affordable medicines to patients.
|BioReliance® End-to-End Biodevelopment Center